Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs ImmunityBio Inc. Common Stock (IBRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs ImmunityBio Inc. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while ImmunityBio Inc. Common Stock trades at $10.51 (market cap $10.51B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and ImmunityBio Inc. Common Stock is more actively traded (10,445,785 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and ImmunityBio Inc. Common Stock for 1 Days on average.
| HALO | IBRX | |
|---|---|---|
Market Cap | $12.58B | $10.51B |
Volume | 2,179,278 | 10,445,785 |
Sector | Health | Health |
52-Week High | $115.22 | $11.55 |
52-Week Low | $61.63 | $1.98 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $14.49B | $10.97B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →
